title: Conservative or surgical treatment for high-risk patients with thoracic empyema?
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Barbetakis
authors.forename: Christos
authors.initials: C
authors.lastname: Asteriou
authors.forename: Athanassios
authors.initials: A
authors.lastname: Kleontas
authors.forename: Vassilios
authors.initials: V
authors.lastname: Lagopoulos
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Salveridis
mesh_terms: D016724:Empyema, Pleural / Q000175:diagnosis / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D018579:Patient Selection; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D020775:Thoracic Surgery, Video-Assisted; D019616:Thoracic Surgical Procedures / Q000009:adverse effects; D013908:Thoracotomy; D015912:Thrombolytic Therapy / Q000009:adverse effects; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator